The GLOW Marketing Playbook | Ordinary Peptides

The GLOW Marketing Playbook | Ordinary Peptides
Reading Time: 16 mins
Wellness & Industry Marketing Regulation Business
Investigative Business Journalism

The GLOW Marketing Playbook: How a Peptide Blend Became a Brand Before the Science Caught Up

A Pilates instructor in Los Angeles, a TikTok hashtag with millions of views, a pricing spread from $279 to $439, and a regulatory environment that shifted twice in twelve months. The story of GLOW is the story of how a marketing label outran pharmacology.
2026 · By the Ordinary Peptides Research Team

A Vial With a Hashtag

If you opened TikTok in late 2024 and searched #glowprotocol, the algorithm did the rest. A Pilates instructor in West Hollywood holding up a small vial. A mid-thirties tech executive in Austin describing his "biological optimization stack" with the calm confidence of a person who has read three Substack newsletters about longevity. A skincare influencer with before-and-after photos that may or may not have involved the same person. The hashtag accumulated tens of millions of views over the course of fourteen months. Behind the hashtag sat a market. Glossy declared 2025 "the year injectable peptide therapy went mainstream." Inc. Magazine, in a November 2025 piece by healthcare attorney Sara Shikhman, called the wellness peptide industry "the Wild West." NewBeauty, in early 2026, ran an explainer that cheerfully referred to "glow stacks" as something that "social media loves." A Glossy podcast in February 2026 listed the term alongside "wolverine stack" and "Barbie peptide" as established slang for community-derived peptide combinations. In the middle of this sits the actual product. Or rather, the absence of one. Because GLOW, the thing being sold under that label across med spas and telehealth platforms and research-only vendors, is not a peptide. It is a brand. The chemistry behind the brand is well-documented and lives on the GLOW research compound page. This article is about the brand itself: how it was built, how it is sold, what it means to call something "GLOW" when no two clinics agree on the recipe, and where the regulatory environment is heading after Robert F. Kennedy Jr. went on Joe Rogan in February 2026 and changed the weather.
A note before going further Nothing in this article is medical advice. The components most commonly combined under the GLOW label are not approved by the FDA for human therapeutic use. Some are on the WADA prohibited list. This piece is about industry structure and marketing, not protocols. For the science of the components, see the linked product pages.

A Brand With Many Recipes

Walk into five different wellness clinics that sell GLOW and you will be sold five different products at five different prices. Miami Bariatric and Plastic Surgery offers a GLOW protocol at $439, structured around a four-to-six-week cycle, with statewide telehealth fulfillment for Florida residents. Florida Surgery & Weight Loss, operating out of Hollywood, sells what is functionally a similar product at the same $439 price point with similar telehealth scaffolding. AH-Clinics in San Diego positions theirs around skin rejuvenation and pairs the injection with topical and laser aesthetic services. Medical Health and Wellness markets a "Glow Blend Peptide Pack." Drip Hydration, in a December 2025 explainer, described "the glow peptide stack" as something now used "in wellness, recovery, and aesthetic health circles." Ordinary Peptides, the parent of this article, supplies a research-grade GLOW preparation at $279. None of these products are the same as the others. Concentrations differ. Component lists vary. Some clinics add NAD+ or glutathione or vitamin C. Some use higher GHK-Cu. Some lower TB-500. There is no canonical formula. There is no standardization body. There is, in the FDA's view, no approved product called GLOW at all. What they share is the name. The name is doing a lot of work. It signals "aesthetic outcome" rather than "biochemistry," which is what the customer is buying anyway. It is short, capitalized, easy to type into Instagram captions. It can be applied to a slightly different recipe next quarter without any legal or commercial penalty, because there is no recipe to begin with. And it is, importantly, not anyone's intellectual property. Twelve clinics can sell GLOW simultaneously and none of them owe royalties to any of the others.
"GLOW is a commercial marketing name used by multiple wellness clinics and compounding pharmacies for injectable blends typically containing BPC-157, TB-500, and GHK-Cu. There is no single standardised product called GLOW." — from the editorial review on the Ordinary Peptides product page

The Marketing Playbook

If you look at how the major operators in this space position themselves, the same five moves keep showing up. The playbook is not formal. Nobody publishes it. But it is consistent enough across med spas, telehealth platforms, and research-only vendors that it is fair to call it a playbook. Move one: name the outcome, not the chemistry. A peptide combination doesn't sell. A brand sells. So you give the combination a brand name that describes what the customer wants, not what is in the vial. GLOW for skin and aesthetic positioning. KLOW for gut and inflammation, with KPV added. "Wolverine Stack" for masculine recovery and tendon repair. "Barbie Peptide" for melanotan, because the cultural reference is funnier than the chemistry. The naming serves three commercial functions at once. It is memorable. It is searchable. And it is patent-around-able. You cannot patent BPC-157. You can absolutely build a brand identity around the word GLOW. Move two: tell a synergy story. Three peptides become a three-phase narrative. Signal, repair, regenerate. "Three peptides, one healing process." The story is structurally satisfying because it has a beginning, middle, and end. Whether the synergy story matches what is happening biologically is a separate question, and one the marketing copy is not under any obligation to answer. The mechanistic plausibility is enough. Plausibility, in this market, is a sales asset. Move three: drape it in medical authority. "Physician-supervised." "Medical-grade purity." "Sourced from FDA-registered compounding pharmacies." That last phrase, in particular, is technically true for some kinds of pharmaceutical manufacturing oversight while being meaningfully false for the specific peptides being sold. In the marketing copy the distinction collapses. Telehealth platforms make this easier still. Most online peptide-prescribing platforms allow customers to obtain a prescription without ever speaking to a physician on video. An asynchronous form is enough. Medical authority becomes a copywriting device, not a clinical practice. Move four: build a three-channel distribution. Same product, three audiences, three price points.
  • Med spas and brick-and-mortar wellness clinics. $400 to $500 per cycle. High-touch, high-price. The leather chairs, the registered nurse, the framed certificate on the wall, the post-procedure water with cucumber. The peptide itself is almost a justification for the visit. The visit is the product.
  • Telehealth platforms. $200 to $400. Hone, Henry Meds, Marek Health, BioLongevity Labs, plus dozens of regional players. Asynchronous intake, mail-order vials, mid-tier pricing. This is where most of the volume happens.
  • Research-only peptide vendors. $200 to $300. Disclaimer-protected, lowest price, technically not for human consumption. Customers know what they are doing. The vendors know what the customers are doing. Everyone agrees not to mention it on the product page.
The three channels look like competitors. Functionally they are a funnel. Customers who can afford the med spa graduate to telehealth for refills. Customers who run out of patience with telehealth pricing find the research vendors. Dissatisfied customers from any channel find a different channel. The market sorts itself. Nobody loses the customer; the customer just shifts which logo they identify with. Move five: borrow the influencer engine. You don't need to build the cultural authority from scratch. You inherit it. Liana Levi, founder of Forma Pilates in Los Angeles, has been talking about BPC-157 during Instagram AMAs for over a year. Jay Campbell, formerly known for testosterone-optimization content, launched BioLongevity Labs in November 2024, one month after RFK Jr. publicly aligned himself with peptides on the campaign trail. Joe Rogan has been recommending BPC-157 on his podcast since 2021. Jeremy Renner, recovering from his 2023 snowplow accident, told Modern Wisdom the peptide helped him heal. Dr. Molly Maloof, a Stanford lecturer, told The San Francisco Standard last fall that "we're going to see a lot of the gray market become the white market in the next decade." Each individual mention is small. The aggregate is a cultural soundtrack.

The Regulatory Whiplash, 2023 to 2026

For about thirty months, this market operated under a regulatory ceiling that was being actively held down. In September 2023, the FDA placed nineteen peptides on its 503A Category 2 list. Category 2 means "significant safety risks" and effectively bars compounding pharmacies from preparing the substance for human use. Most of the chemistry behind GLOW, KLOW, the Wolverine Stack, and the rest of the brand-name protocol economy was on that list. Operators adapted. Compounding pharmacies that had been preparing the peptides quietly stopped. Clinics that had been selling them pivoted to research-only labels and overseas-sourced product. Telehealth platforms restructured their fulfillment chains. The market did not shrink. It routed around the regulation. Then on February 27, 2026, HHS Secretary Robert F. Kennedy Jr. went on the Joe Rogan Experience and described himself as "a big fan" of peptides. He said he expected approximately fourteen of the nineteen Category 2 peptides to be moved back to Category 1 — the status that does permit compounding under physician prescription. Kennedy framed the prior FDA decision as an overreach and posted on X that the move would "begin to restore regulated access and immediately begin shifting demand away from the black market." On April 23, 2026, the peptides came off Category 2. Not because the FDA approved them. Because the original nominators withdrew their nominations and the procedural status defaulted out. The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24, 2026 to discuss whether any of these substances should formally land on Category 1. Read that timeline quickly and it sounds like the regulation eased. Read it carefully and it does not. "Came off Category 2 because the nominators withdrew" is not the same as "approved." It is closer to "the FDA temporarily lost the procedural mechanism for blocking them, while a different procedural mechanism is being built." Healthcare attorneys have been blunt about the distinction. STAT News, in a critical First Opinion piece by Dr. Adriane Fugh-Berman published April 29, 2026, argued the shift "could reopen access to unproven compounds" and used the headline RFK Jr.'s peptide push could unleash risky drugs. For the wellness peptide industry the immediate effect has been less about new legality and more about new ambiguity. Which is, commercially, almost as good. Compounding pharmacies that had pulled BPC-157 from their formularies are quietly bringing it back. Telehealth platforms are running soft launches. Med spas are scheduling "GLOW reactivation" promotional emails for July, timed to whatever the advisory committee meeting produces.

The WADA Layer, Which Has Not Moved

There is a regulatory dimension the wellness marketing copy almost never foregrounds, and it should. BPC-157 has been on the World Anti-Doping Agency's prohibited list since 2022, under category S0. TB-500, classified under S2, has been prohibited longer. The U.S. Department of Defense has formally adopted WADA categories for service-member testing. The NFL, the UFC, the NCAA, and most professional leagues either name BPC-157 explicitly or include it under broader peptide-hormone bans. WADA's position is independent of FDA's. If the FDA places BPC-157 on Category 1 next month, BPC-157 remains S0 prohibited. The reclassification narrative coming out of Washington has no effect on anti-doping enforcement. There is no Therapeutic Use Exemption available for these substances. A four-year competition ban is the standard sanction.
A real case On April 7, 2025, the Canadian Centre for Ethics in Sport announced a four-year sanction against Emma Brooks, a U SPORTS volleyball player at MacEwan University, for using BPC-157 and TB-500 between August and September 2024. The sanction ends December 3, 2028. Brooks did not contest the violation; the suspension was confirmed by deemed waiver. (Source: SIRC / Canadian Centre for Ethics in Sport.)
A buyer who is also a competitive athlete — collegiate, semi-pro, even amateur in tested federations — can move through a wellness clinic intake form, a telehealth consult, and a delivered vial without ever encountering the WADA status of what they are about to inject. The clinics are not lying about it. They are simply not foregrounding it. Whether that is informed consent in any meaningful sense is a question the industry has not seriously confronted.

The "Research Only" Workaround

There is a third regulatory channel beneath all of this, and it is the one the FDA has had the hardest time touching. The research-chemical channel. If a vial is labeled "for laboratory research only, not for human consumption," and the vendor sells it as a research compound rather than a drug, U.S. enforcement of the sale itself has historically been minimal. The disclaimer shifts liability. It does not create real legal cover (the FDA is clear that intended use, not labeling, determines whether something is regulated as a drug), but enforcement against research-only sellers has historically been rare. Whether that changes under HHS Secretary Kennedy's stated intent to drive demand "out of the black market" is one of the open questions of 2026. A pharmacist contributor at SafeMedication.com, writing in late April 2026, framed it this way: when the FDA blocked compounding in 2023, "compounded peptides continued to be sold, just obtained by different means. Overseas suppliers are now selling compounded peptides online, made 'legal' by adding the label 'for research purposes only' to the product." The pattern is not unique to peptides. It is the pattern of every gray-market consumer health category since the dietary-supplement era.

Where This Goes Next

Three things are likely to happen between now and the end of 2027. First, the July 2026 advisory committee meeting will produce a recommendation, and that recommendation will be partial. Some peptides (those with the strongest preclinical safety data and most plausible therapeutic indications) will move toward Category 1. Others, especially those with weaker mechanism stories or specific safety concerns, will stay where they are. The market will read the recommendation as a green light, regardless of how narrowly it is written. Second, the mainstream pharmaceutical industry will start to circle. Eli Lilly and Novo Nordisk have already restructured their telehealth-distribution strategies around GLP-1 demand. If BPC-157 acquires legitimate Category 1 status, expect a real pharma sponsor to put a phase-II trial on the books within twelve months. The economics still don't favor it (the underlying sequences are not patentable as new chemical entities), but a delivery-system patent or formulation patent could shift the math. Watch the transdermal-patch space, and watch oral peptide formulations. Third, consolidation. The med-spa peptide industry is currently fragmented across thousands of independent clinics, telehealth startups, and research-only vendors. As reclassification clarifies the legal landscape, expect roll-ups. Sara Shikhman's law firm Lengea Law (which serves "med spas, IV hydration businesses, mental health practices, and dental offices") landed at #679 on the 2025 Inc. 5000 list with 615% three-year growth, a number that tells you what kind of legal volume the wellness-clinic sector has been generating. The first major exit will probably be a telehealth platform. Don't be surprised if it happens before the end of 2027.

What This Means in Practice

Practical takeaways, without the marketing tone.
  • Brand recognition is not quality assurance. "GLOW" tells you nothing about purity, dosing, sterility, or sourcing. Two products under the same name can differ by 30% on label-claim potency. Certificate of Analysis from the actual lot, not the brand, is what matters.
  • The legal situation will change again. The peptide regulatory environment in May 2026 is not the environment from January 2026, and probably not the environment that will exist in October 2026. Anyone making business or personal decisions on the assumption that current rules are stable is likely to be surprised.
  • Athletes carry separate risk. WADA does not care what the FDA does. If you compete at any level subject to anti-doping testing, the GLOW protocol you bought from a med spa is a four-year ban waiting to happen.
  • "Research only" is not a legal shield for the buyer. The disclaimer protects the vendor more than the customer. Personal use occupies an enforcement-discretion gray zone that Kennedy's HHS has signaled it might tighten, even as it loosens compounding rules.
  • For investors and operators, the next eighteen months will sort out the channel mix. Telehealth, med spa, and research-only have been parallel structures. After July 2026, two of them will start to look like the same business.

The Bottom Line

GLOW is a case study in what modern wellness marketing actually does. It is biologically coherent enough to feel substantive. It is regulatorily ambiguous enough to be widely available. It is culturally aligned with the longevity-and-optimization moment in a way that almost nothing else in pharma quite manages. Whether it is a meaningful therapy or sophisticated theater is a question this industry has no incentive to resolve. Until controlled human trials of the combination exist (and they don't, not yet), every claim about GLOW's effects is extrapolation from animal models and individual-compound studies on the underlying chemistry. What is not extrapolation is the marketing. The playbook works. The market grew. The regulatory environment is moving in the industry's direction. The TikTok hashtag keeps adding views. The science can wait. The brand has not been waiting.
Editorial Disclosure Ordinary Peptides supplies the components most commonly combined under the GLOW label as research-grade material. For the chemistry, mechanism, evidence base, and regulatory status of the components themselves, the scientific reference page for GLOW covers the science in detail. This article is editorial coverage of the industry, not a product description. For the broader research-peptide category, see the regenerative peptides section.
Sources & Further Reading
  1. Glossy. "Injectable peptide therapy went mainstream in 2025, priming consumers for the next big wellness wave." January 5, 2026. glossy.co
  2. Shikhman, Sara. "Peptides Are Booming in Wellness Clinics." Inc. Magazine, November 14, 2025. inc.com/sarashikman
  3. Brookshire, Bethany. "The science behind the peptide craze." Scientific American, April 2026. scientificamerican.com
  4. NewBeauty. "Everything to Know about Trendy Peptide Injections and Glow Stacks." April 2026. newbeauty.com
  5. Glossy Beauty Podcast. "Peptides 101: How BPC-157 and 'peptide stacks' are driving wellness culture." February 12, 2026. glossy.co/podcasts
  6. BioPharma Dive. "FDA moves toward easing restrictions on certain peptides." 2026. biopharmadive.com
  7. Frier Levitt. "The Peptide Landscape Is Shifting: What Secretary Kennedy's Joe Rogan Interview Could Mean for the Compounding Industry." March 10, 2026. frierlevitt.com
  8. STAT News First Opinion. "RFK Jr.'s peptide push could unleash risky drugs." April 29, 2026. statnews.com
  9. LumaLex Law. "RFK Jr, Peptides & FDA Category 2: What's Really Changing?" March 2026. lumalexlaw.com
  10. Canadian Centre for Ethics in Sport. "U SPORTS Volleyball Athlete Suspended for the Use of BPC-157 and TB-500." April 7, 2025. sirc.ca
  11. Banned Substances Control Group. "BPC-157: Rules and Risks for Athletes and Military Service Members." February 19, 2026. bscg.org
  12. Drip Hydration. "The Glow Peptide Stack: A Modern Approach to Skin Health, Energy, and Recovery." December 2025. driphydration.com
  13. SafeMedication.com. "Peptide Therapy: Benefits, Risks, and What You Need to Know." April 27, 2026. safemedication.com
  14. Inc. 5000 list (2025). Lengea Law: #679, 615% three-year growth. inc.com/profile/lengea-law
  15. WADA Prohibited List 2024-2026. wada-ama.org
Editorial Desk · All external links open in a new tab · 2026